Increased expression of IL-37 in patients with graves' disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Li, Yanqun ^a,b   Wang, Zi ^a,b   Yu, Ting ^a,b   Chen, Bingni ^a,b   Zhang, Jinshun ^a,b   Huang, Kunzhao ^a,b   Huang, Zhong ^a,b  

^a Shenzhen University   (China)

^b SHENZHEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 37; INTERLEUKIN 6; LIOTHYRONINE; MESSENGER RNA; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; IL37 PROTEIN, HUMAN; INTERLEUKIN 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE SEQUENCE; GRAVES DISEASE; HUMAN; HUMAN CELL; IL 17 GENE; IL 37 GENE; IL 6 GENE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TNF ALPHA GENE; UPREGULATION; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GRAVES DISEASE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RNA, MESSENGER; YOUNG ADULT;

EID: 84907274209     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107183     Document Type: Article

References (46)

1. Anthony P. Weetman, MD, D SC (2000) Graves's disease. N Engl J Med 343: 1236-1248.
2. Rees Smith B, McLachlan SM, Furmaniak J (1988) Autoantibodies to the thyrotropin receptor. Endocr Rev 9: 106-121.
3. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM (1998) The thyrotropin (TSH) receptor: Interaction with TSH and autoantibodies. Endocr Rev19: 673-716.
4. Jayne A. Franklyn (1994) The Management of Hyperthyroidism. N Engl J Med 330: 1731-1738.
5. Bartalena L, Brogioni S, Grasso L, Martino E (1993) Increased serum interleukin-6 concentrations in patients with subacute thyroiditis: relationship with concomitant changes in serum T4-binding globulin concentrations. Journal of Endocrinological Investigation 16: 213-218.
6. Bartalena L, Grasso L, Brogioni S, Aghini-Lombardi F, Braverman LE, et al. (1994) Serum interleukin-6 in amiodarone-induced thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism 78: 423-427.
7. Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, et al. (1996) Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. Journal of Clinical Endocrinology and Metabolism 81: 2976-2979.
8. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, et al. (2000) Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. European Journal of Endocrinology 143: 197-202.
9. Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin M (1999) Serum cytokines in thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism 84: 435-439.
10. Al-Humaidi MA (2000) Serum cytokines levels in Graves' disease. Saudi Medical Journal 21: 639-644.
11. Bossowski A, Urban M (2001) Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter. Journal of Pediatric Endocrinology and Metabolism 14: 741-747.
12. Celik I, Akalin S, Erbas T (1995) Serum levels of interleukin 6 and tumor necrosis factor-a in hyperthyroid patients before and after propylthiouracil treatment. European Journal of Endocrinology 132: 668-672.
13. Lakatos P, Foldes J, Horvath C, Kiss L, Tatrai A, et al. (1997) Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. Journal of Clinical Endocrinology and Metabolism 82 (1): 78-81.
14. Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D (2006) The effects of tumour necrosis factor-alpha and interleukin-1 on an in vitro model of thyroid-associated ophthalmopathy: contrasting effects on adipogenesis. Eur J Endocrinol 155: 395-403.
15. Di Peng, Bingchuan Xu, Ye Wang, Hui Guo, Jiang Y., et al. (2013) A high frequency of circulating Th22 and Th17 cells in patients with new onset Graves'Disease. PloS one 8: e68446.
16. Jianrong Li, Fuyuan Hong, Jinyang Zeng, Guoliang Huang (2013) Functional interleukin-17 receptor A are present in the thyroid gland in intractable Graves disease. Cellular Immunology 281: 85-90.
17. Kiziltunc A,Basoglu M, Bahattin AVC, Capoglu I (1999) Serum IL-6 and TNF-α in Patients With Thyroid Disorders. Tr J of Medical Sciences 29: 25-29.
18. Bossowski A, Urban M (2001) Serum Levels of Cytokines in Children and Adolescents with Graves'Disease and Non-toxic Nodular Goiter. Journal of Pediatric Endocrinology & Metabolism 14: 741-747.
19. Papanicolaou DA (2000) Euthyroid sick syndrome and the role of cytokines. Reviews in Endocrine and Metabolic Disorders 1(1-2): 43-48.
20. Pan G, Risser P, Mao W, Baldwin DT, Zhong AW, et al. (2001) IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine 13: 1-7.
21. Busfield SJ, Comrack CA, Yu G, Chickering TW, et al. (2000) Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics 66: 213-216.
22. Kumar S, McDonnell PC, Lehr R, Tierney L, Tzimas MN, et al. (2000) Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem 275: 10308-10314.
23. Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE, et al. (2000) Four new members expand the interleukin-1 superfamily. J Biol Chem 275: 1169-1175.
24. Taylor S L, Renshaw BR, Garka K E, Smith DE, Sims J, et al. (2002) Genomic organization of the interleukin-1 locus. Genomics 79: 726-733.
25. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, et al. (2010) IL-37 is a fundamental inhibitor of innate immunity. Nature immunology 11(11): 1014-1022.
26. Bufler P, Gamboni-Robertson F, Azam T, Kim SH, Dinarello CA (2004) Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem J 381: 503-10.
27. Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, et al. (2011) Interleukins, from 1 to 37, and interferon-γ: Receptors,functions, and roles in diseases. Journal of Allergy and Clinical Immunology 127: 701-721.
28. McNamee EN, Masterson JC, Jedlicka P, McManus M, Grenz A, et al. (2011) Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci USA 108: 16711-6.
29. Sakai N, Van Sweringen HL, Belizaire RM, Quillin RC, Schuster R, et al. (2012) Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterology Hepatology 27: 1609-16.
30. Dov B. Ballak, Suzhao Li, Janna A. van Diepen, et al. (2013) IL-37 protects against obesity-induced inflammation and insulin resistance. Cytokine 63: 245-246.
31. Teng X, Hu Z, Wei X, Wang Z, Guan T, et al. (2014) IL-37 Ameliorates the Inflammatory Process in Psoriasis by Suppressing Proinflammatory Cytokine Production. The Journal of Immunology 22: 1300047.
32. Imaeda H, Takahashi K, Fujimoto T, Kasumi E, Ban H, et al.(2013) Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol 172: 410-6.
33. Wan Z, Sun Z, Song F (2014) Downregulated interleukin 37 expression associated with aggravation of intervertebral disc degeneration. Int J Clin Exp Pathol 7(2):656-662.
34. Ye L, Ji L, Wen Z, Zhou Y, Hu D, et al. (2014) IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity. Journal of translational medicine 12(1): 69.
35. Marshall WJ, Bangert SK (2008) Clinical Chemistry. Elsevier Health Sciences Press 182p.
36. Monaco F (2012) Thyroid Diseases. CRC Press. 379p.
37. Bulau AM, Fink M (2011) In Vivo Expression of Interleukin-37 Reduces Local and Systemic Inflammation in Concanavalin A-Induced Hepatitis. The Scientific World Journal 11: 2480-2490.
38. Bartalena L, Brogioni S, Grasso L, Martino E (1993) Increased serum interleukin-6 concentrations in patients with subacute thyroiditis: relationship with concomitant changes in serum T4-binding globulin concentrations. Journal of Endocrinological Investigation 16: 213-218.
39. Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D (2006) The effects of tumour necrosis factor-alpha and interleukin1 on an in vitro model of thyroid-associated ophthalmopathy: contrasting effects on adipogenesis. Eur J Endocrinol 155: 395-403.
40. Weetman AP, Ress AJ (1988) Synergistic effects of recombinant tumour necrosis factor and interferon-gamma on rat thyroid cell growth and ia antigen expression. Immunology 63: 285-9.
41. Buscema M, Todd I, Deuss U, Hammond L, Mirakian R, et al. (1989) Influence of tumor necrosis factor-α on the modulation by interferon-γ of HLA class II molecules in human thyroid cells and its effect on interferon-γ binding. Journal of Clinical Endocrinology and Metabolism 69: 433-439.
42. Simmonds MJ, Heward JM, Howson JM, Foxall H, Nithiyananthan R, et al. (2004) A systematic approach to the assessment of known TNF-alpha polymorphisms in Graves' disease. Genes Immun 5: 267-273.
43. Shiau MY, Huang CN, Yang TP, Hwang YC, Tsai KJ, et al. (2007) Cytokine promoter polymorphisms in Taiwanese patients with Graves' disease. Clin Biochem 40: 213-217.
44. Sato K, Satoh T, Shizume K, Ozawa M, Han DC, et al. (1990) Inhibition of 125I organification and thyroid hormone release by interleukin-1, tumor necrosis factor-alpha, and INF-gamma in human thyrocytes in suspension culture. J Clin Endocrinol Metab 70: 1735-1743.
45. Davis PJ (2008) Cytokines and growth factors and thyroid hormone. Curr Opin Endocrinol Diabetes Obes 15: 428.
46. Falgarone G, Heshmati HM (2013) Mechanisms in endocrinology: Role of emotional stress in the pathophysiology of Graves' disease. European Journal of Endocrinology 168: R13-R18.